Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities
Open Access
- 1 May 2015
- journal article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 9, 2627-2634
Abstract
The presence of polymorphisms in the CYP2D6 gene may modulate enzyme level and activity, thereby affecting individual responses to pharmacological treatment. Here, we compared the prevalence of the CYP2D6*10, *4, and 14* alleles in an Iranian population of different ethnicities with those of other populations. Allele and genotype frequency distributions of CYP2D6*10 variants and predicted phenotypes including extensive metabolizers, intermediate metabolizers, and poor metabolizers were analysed in blood samples of 300 unrelated healthy individuals in an Iranian population using polymerase chain reaction (PCR)-restriction fragment length polymorphism, PCR-single-strand conformation polymorphism, and direct genomic DNA sequencing. The CYP2D6*4 (G1846A) and *14 (G1758A) allelic frequencies were not detected in different ethnicities, demonstrating the absence of a significant contribution of these alleles in Iranian populations. However, the T/T, C/T, and C/C genotype frequencies of the CYP2D6*10 allele were significantly different (PCYP2D6*10 allele was significantly high in the Lure (PPCYP2D6*10 allele in central Iran was the highest (PPCYP2D6*10 allele was significantly a bit high (PCYP2D6*4 (G1846A) and *14 (G1758A) alleles in Iranian populations of different ethnicities, the prediction of the CYP2D6*10 allele is required in drug research and routine treatment, where the information would be helpful for clinicians to optimize therapy or identify persons at risk of adverse drug reactions before clinical trials. Approximately 39.3% of subjects (24.3% homozygous T/T CYP2D6*10 as poor metabolizers and 15% heterozygous C/T CYP2D6*10 as intermediate metabolizers) had this allele; therefore, the harmful effects of drugs are relatively common among Iranians.Keywords
This publication has 31 references indexed in Scilit:
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspectsPharmacology & Therapeutics, 2007
- ‘Drug Reactions, Enzymes, and Biochemical Genetics‘: 50 years LaterPharmacogenomics, 2007
- Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical PracticePharmacological Reviews, 2006
- Common mutant alleles of CYP2D6 causing the defect of CYP2D6 enzyme activity in a Japanese populationBritish Journal of Clinical Pharmacology, 2003
- Heterogeneity of the CYP2D6 gene among Malays in MalaysiaJournal of Clinical Pharmacy and Therapeutics, 2001
- How to Manage Individualized Drug Therapy: Application of Pharmacogenetic Knowledge of Drug Metabolism and TransportClinical Chemistry and Laboratory Medicine (CCLM), 2000
- CYP2D6 genotypes in a Japanese population: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10Pharmacogenetics, 2000
- Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjectsPharmacogenetics, 1995
- Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.Molecular Pharmacology, 1994